The Institute for Clinical and Economic Review (ICER) is an independent, non-profit research institute that conducts evidence-based reviews of health care interventions, including prescription drugs, other treatments, and diagnostic tests. In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices. ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs.

The US health system is distinctly innovative but fails to provide high-value care to all patients at a price they and the nation can afford. To improve access and affordability while retaining the incentives necessary for future innovation, ICER transparently reviews all available evidence to help align a treatment’s price with how well it improves the lives of patients and their families.

The fundamental questions are few:

  • Based on the evidence, how much better is a new treatment at extending or improving patients’ lives?
  • What would a fair price be, based on the clinical evidence as well as patients’ perspectives about the outcomes that are most important to them?
  • And how can patients, clinical experts, and insurers translate the evidence into insurance coverage that ensures the best patient outcomes?

The end goal: sustainable access to high-value health care for all Americans.